Norwood, Massachusetts-based, Corbus Pharmaceuticals Holdings, Inc., recently announced their Chief Executive Officer, Yuval Cohen, Ph.D., has been invited to present at two upcoming investor conferences. Both presentations will highlight and discuss Corbus’ lead pipeline therapeutic for serious inflammatory and fibrotic conditions, Resunab™, which has as its active ingredient, ajulemic acid – a non-psychoactive cannabinoid acid, capable of inducing apoptosis in harmful T-cells. At present, Corbus is focused on developing Resunab for cystic fibrosis and systemic sclerosis.
Dr. Cohen is scheduled to present the latest company updates and product findings at the following January investor conferences:
- Biotech Showcase 2015
- Date: Wednesday, January 14, 2015
- Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
- Venue: Parc 55 Wyndham Union Square, San Francisco, CA
- Noble Financial Capital Markets’ 11th Annual Investor Conference
- Date: Tuesday, January 20, 2015
- Time: 9:00 a.m. Eastern Time
- Venue: Club Med, Sandpiper Bay, FL
The presentations will provide the conferences’ attendees with a corporate-level overview, focused primarily on Corbus’ research and development plans for Resunab as an innovative “off-switch” for inflammation and consequent fibrosis. The Company’s website will be providing live webcasts of the two presentations under the IR Calendar in the News and Events section of the Investor Relations page, and will remain available for one month starting 2 hours after each presentation is concluded.
At present, Corbus is preparing to launch Resunab™ into Phase 2a clinical testing, and is awaiting the drug’s Investigational New Drug approval from the US Food and Drug Administration. For more information, visit www.corbusoharmaceuticals.com, or dial +1 (617) 963-0100.
In other news on potential treatments for cystic fibrosis, Vertex Pharmaceuticals recently received a supplemental new drug application (sNDA) from the US FDA for their lead CF treatment, Kalydeco® (ivacaftor), formulated to treat the disease in patients 6 years and older, carrying the R117H mutation in the CF transmembrane conductance regulator (CFTR) gene. The agency partially based its approval on encouraging findings from a Phase III clinical trial for Kalydeco on 69 CF patients with the R117H mutation. An estimated 500 people or more in the United States have this specific mutation. With Kalydeco’s sNDA, over 3,100 people in North America, Europe and Australia will have a new treatment option.